anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To solve problems such that although oxydol (2.5 to 3.5% aqueous hydrogen peroxide solution) has efficacy of disinfection of oral mucous membrane and cleaning of teeth, its retentive property on a tray is not good, and it is inconvenient for use on performing 3DS (dental drug delivery system), by changing the oxydol to gel to improve the retentive property on a tray for a row of teeth, and also to provide a tool for agitating, mixing and carrying the gel.  <P>SOLUTION: This tooth paste component is provided by changing the oxydol into the gel and having a prescribed preparation form adjusted to be used for the 3DS performed in a dental clinic. Thereby, it is possible to give prescribed viscosity to the oxydol and have the retentive property on the tray for the teeth row. Also the tool for agitating, mixing and carrying the gel is provided by consisting of a needle made from a plastic (tip end part) for agitating and mixing the gel, and a syringe made from a plastic (a main body) for carrying the gel. Thereby, it becomes easy to agitate, mix and carry the gel.  <P>COPYRIGHT: (C)2008,JPO&INPIT
The study population contained a broad spectrum of endoscopic disease and clinical activity. At entry to the trial patients had active disease defined by the presence of a modified UCDAI score between 4 and 10.1 Only patients who had a MMCS endoscopy subscale score according to a single central reader (n= 194 of 281 participants) were eligible for assessment in the current study.
It is the standard of care that served as the intervention. The control group received the standard care for patients on hemodialysis. The standard care involves a 10 -15-minute face-to-face health teaching of their treatment regimen including pharmacologic management, dialysis schedule, dietary and fluid restrictions or nutritional therapy, care for vascular access, and other necessary lifestyle modifications.
INTRODUCTION: The Lower Anogenital Squamous Terminology (LAST) Project recommended unified classification for HPV-associated squamous lesions of the lower anogenital tract, using a 2-tiered nomenclature in 2013. Adherence to the new nomenclature worldwide is unknown. This study aims to assess the trend of the use of the two-tiered High Squamous Intraepithelial Lesion and Low Squamous Intraepithelial Lesion (HSIL/LSIL) as opposed to the traditional three-tiered Anal Intraepithelial Neoplasia (AIN I/II/III) classification as suggested by the LAST Project.
METHODS: A literature search on full-text English language studies of premalignant anal lesion was performed on PubMed from 2002-2022. The studies were categorized by continent, and the prevalence of HSIL/LSIL classification vs AIN I/II/III was calculated.
RESULTS: 546 studies and 251 studies were identified using the AIN I/II/II and the HSIL/LSIL classification respectively. Global trend suggested a statistically significant downward trend in the use of the two-tiered nomenclature system in publications globally. Regional trend including North America, Europe, and other (Asia and Latin America) showed variance in adoption of the two-tiered nomenclature system.
CONCLUSION: Despite multidisciplinary collaborative effort, adherence to the recommendations to use the two-tiered system for HPV-associated premalignant anal lesions continues to be suboptimal. Further efforts are needed to identify the cause of poor adherence to be able to create strategies that reinforces unification of terminology and integration of LAST the recommendations.
PURPOSE: To express a gene coding desired antigen in a liver cell and produce a monoclonal antibody by introducing the gene into an initial culture liver cell of an animal by 'Lipofectin(R)'. CONSTITUTION: A complex of a cationic liposome with a gene coding a desired antigen is formed and the complex is introduced into an initial cultured liver cell of an animal. The cationic liposome is bound to the circumference of DNA having a negative charge and forms an artificial lipid double layer. Besides, since the cell has negative charge and readily can take positive charge therein and an unit membrane forms the lipid double layer, the cell fuses with the cationic liposome. The resultant liver cell immunizes a same kind of animal as the derived animal. Immunizing operation is carried out by subjecting a suspension of the liver cell into intraperitoneal or intravenous administration.
An aqueous high-viscosity gingival hemostatic retraction paste includes greater than 45% by weight kaolin clay, greater than 20% by weight aluminum chloride hexahydrate, and less than 25% by weight water. The paste may also include a thickening agent. The paste may include thickening agent in an amount of between approximately 0.25% and 1% by weight. The paste may also include a desensitizer. The paste may include desensitizer in an amount between approximately 0.5% and approximately 5% by weight. A compression cap for application to a prepared tooth during a gingival retraction procedure includes a body having a first end with an opening and defining a hollowed-out center extending into the body from the opening, wherein the compression cap comprises a wax compound. A method for applying desensitizer to a prepared tooth during a gingival retraction procedure includes applying a desensitizer compound to an inner surface of the compression cap.
OBJECTIVES: This study evaluated the effectiveness, psychological effects, and sleep quality using intramuscular diazepam infusion compared with placebo in patients with herpes zoster (HZ)-related pain.
METHODS: The patients were randomized to either the diazepam or control group. The diazepam group received an intramuscular injection of diazepam for 3 consecutive days, while the control group received an intramuscular injection of 0.9% normal saline. The primary outcome was pain relief on posttreatment day 4, as measured using the Visual Analog Scale (VAS). Moreover, anxiety and depression were evaluated using the Generalized Anxiety Disorder-7 (GAD7) and Patient Health Questionnaire-9 (PHQ9), respectively. Sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI).
RESULTS: In total, 78 patients were enrolled in the trial. The mean differences in VAS scores between the two groups were 0.62 (P = 0.049) on posttreatment day 3 and 0.66 (P = 0.037) on posttreatment day 4. The effective rates of pain management in the diazepam group ranged from 10.26 to 66.67%, which were higher than those in the control group on posttreatment days 3 and 4 (P < 0.05). The mean difference in PSQI scores between the diazepam and control groups was 1.36 (P = 0.034) on posttreatment day 7. No differences were found in the incidence of analgesia-adverse 1reactions between the diazepam and placebo groups.
CONCLUSIONS: The intramuscular injection of diazepam for 3 consecutive days provides effective pain management and improves the quality of life. Our study suggests that diazepam is more effective than the placebo in patients with HZ-related pain.
TRIAL REGISTRATION: The study was prospectively registered at https://www.isrctn.com/trialist(Registration date: 24/01/2018; Trial ID: ISRCTN12682696).
Common bile duct stones (CBDS) can be complicated with various conditions including biliary pain, acute cholangitis, acute pancreatitis and secondary biliary cirrhosis. CBDS should therefore be removed even if patients are asymptomatic.

Endoscopic retrograde cholangiopancreatography (ERCP) is the cornerstone treatment of CBDS. ERCP is often performed under fluoroscopic guidance. This comprises biliary cannulation whereby the bile duct is achieved with a standard ERCP catheter under fluoroscopy guidance, radiocontrast was injected for confirmation and images of biliary system, location and number of CBDS, biliary sphincterotomy was then performed followed by stone extraction using a standard accessories such as a basket and or balloon. Therefore, the endoscopist, endoscopic staff and patient are potentially exposed to ionizing radiation during ERCP. Endoscopists should always attempt to minimize radiation exposure to the personnel staffs and patients by following the ALARA principle ("As Low As Reasonably Achievable"). ERCP without the use of fluoroscopy is the one method to avoid exposure to radiation. A few retrospective case series have been shown that ERCP can be performed with high success rate without the need for fluoroscopic imaging.

EUS has been proven to have diagnostic accuracy comparable to ERCP in the diagnosis of CBDS, and it's associated with a very low procedure related complications and non-radiation exposure procedure. With EUS performed before ERCP, unnecessary ERCP and its related complications can be avoided in patients without CBDS. In patients with CBDS, the images of pancreaticobiliary tract derived from EUS provide an information regarding the location, size and number of CBDS for guiding therapeutic endoscopy, and allowing a therapeutic ERCP in the same session of sedation. Vohra et al. reported the retrospective case series of EUS - based ERCP in 10 pregnant patients, they have shown that EUS performed prior ERCP can eliminate unnecessary ERCP and achieve in CBDS clearance without the use of fluoroscopy. We have previously reported the use of EUS guided ERCP in the removal of CBDS without fluoroscopy (EGWF) in the pilot study, it showed that EGWF was feasible in selected patients with CBDS. The efficacy of EUS guided ERCP in CBDS removal without fluoroscopy compared with standard ERCP has not been fully assessed. We therefore prospectively investigated the efficacy and safety of EGWF versus ERCP in CBDS removal in a larger patient cohort.
The invention relates to a medicinal composition for treating infantile anorexia and a preparation method thereof, and belongs to the field of traditional Chinese medicines. The infantile anorexia relates to a disease that children dislike eating food, has no appetite and even refuse to eat food. Children with the infantile anorexia have no active desire to eat and hate eating food. The disease is more common in children aged 1-6 years and is more common in urban children. Patients, who are not cured for a long time or receive no treatment or receive wrong treatment, may develop chronic nutritional disorders. Main causes of the infantile anorexia are improper diet, improper nursing, breast milk lack, dependence on milk powder nursing, and late addition of complementary food in babyhood. The infantile anorexia can be caused by factors that children have tender viscera and can be easily affected by exogenous pathogenic factors; children cannot control diet, and spleens and stomachs of children can be easily injured; and spleens and stomachs of children who take chemical medicines too much or too often when the children are ill can be injured. Treatment principles for the disease are to tonify the spleen and the stomach and enhance digestive and absorption abilities, and measures of warming spleen and stomach and resolving dampness, conditioning qi function and benefiting digestion, and nourishing stomach and yin can be taken as supplementary, thereby achieving effects of treating the infantile anorexia, increasing appetite and improving physical health.
To better understand veterans' decisions about germline testing, we conducted a single-site, qualitative study of 32 veterans with advanced prostate cancer. Seven days after oncologist-patient discussions about germline testing, we conducted semistructured interviews with patients to explore their decision-making process using an interview guide. Four of 14 veterans with service-connected disability benefits for prostate cancer declined germline testing for fear of losing benefits because their livelihood depended on these benefits. All 18 veterans without service-connected benefits agreed to testing. Veterans declining germline testing based on this concern can lead to suboptimal cancer care because targeted treatments that could improve their outcomes may go unrecognized. Our findings contributed to new language in the Veterans Benefits Administration Compensation and Pension Manual clarifying that genetic testing showing hereditary predisposition is insufficient to deny service-connected benefits for conditions presumed to be caused by military exposures. Clinicians should communicate this protection when counseling veterans about genetic testing.
SYMLIN should be administered subcutaneously immediately prior to each major meal (≥250 kcal or containing ≥30 grams of carbohydrate).

SYMLIN should be at room temperature before injecting to reduce potential injection site reactions. Each SYMLIN dose should be administered subcutaneously into the abdomen or thigh. Administration into the arm is not recommended because of variable absorption. Injection sites should be rotated so that the same site is not used repeatedly. The injection site selected should also be distinct from the site chosen for any concomitant insulin injection.

SYMLIN and insulin should always be administered as separate injections.

SYMLIN should not be mixed with any type of insulin.

If a SYMLIN dose is missed, wait until the next scheduled dose and administer the usual amount.
This disclosure relates to introducing specified endogenous amiRNA responsive to endogenous primary-miRNAs. This invention allows the degradation of amiRNAs in specific tissues, while allowing amiRNA to silence gene expression in other tissues. No studies or publications have been found describing a similar approach. Any available amiRNA could be modified and any endogenous miRNA could be used as regulator. The invention is highly modifiable and tunable. The experimental validation pipeline is optimized to enable the discovery of the most functional design. This is done through modifying the loop of a given amiRNA to make it complementary to potentially any endogenous miRNA.
Kidney transplantation is the desired treatment of choice in subjects with end-stage kidney disease (ESRD). The average waiting time for subjects to receive a "deceased donor" kidney transplant is 3-5 years. Currently, there are about 60,000 subjects on the national waiting list, and about 13,000-14,000 kidney transplants are performed each year. Approximately, 25% of subjects on the waiting list are "highly sensitized", meaning that they have natural proteins (antibodies) that aggressively protect their bodies from the invasion of foreign proteins. These individuals often have a difficult time accepting transplanted kidneys. The purpose of this study is to identify subjects who are highly sensitized with these antibodies, and treat them in such a way, that it may become possible to transplant kidneys into them. Drugs like atorvastatin (Lipitor) may decrease the levels of these anti-bodies and increase the possibility of these subjects to receive a kidney transplant. This research study is being done because currently, there are very limited and cumbersome treatment options to address this issue, subjects who are highly sensitized with antibodies, may unfortunately wait for a very long time or may never get transplanted.
PROBLEM TO BE SOLVED: To provide a method for readily producing a high-melting terfenadine useful as an antiallergic agent. SOLUTION: An acid a solvent (I) are added to terfenadine to provide a solution of the acid addition salt of the terfenadine. The resultant acid addition salt of the terfenadine is then crystallized and the formed crystal is isolated and subsequently suspended in water or dissolved in a solvent (II). A base is then added to the resultant suspension or solution to thereby produce the substantially pure high-melting terfenadine. Methanol, ethanol and 1-propanol are preferred as the solvents (I) and (II) and may be used in combination and the ethanol is most preferred. The solvents (I) and (II) may be the same or different.
Background: Osteoporosis is defined as an absolute decrease in the amount of bone (volume and/or density). Chronic liver disease is associated with osteoporosis in both adults and children. Bone density is also decreased in the months immediately after liver transplantation, but improves to pretransplant values after 1 to 2 years. Immunosuppressive agents, most notably steroids, are a cause of osteoporosis. However, studies on adults have shown that bone densities afer transplantation continue to improve within the normal range for healthy adults. In the case of children, bone accretion is necessary for growth. Chronic liver disease and transplantation in childhood will have an adverse effect on bone metabolism and the outcome in terms of bone density after the growth period cannot be predicted on individuals transplanted as adults or other transplant groups.
For normal healthy adults, the individual maximum recommended dose of lidocaine HCl with epinephrine should not exceed 7 mg/kg (3.5 mg/lb) of body weight, and in general it is recommended that the maximum total dose not exceed 500 mg. When used without epinephrine the maximum individual dose should not exceed 4.5 mg/kg (2 mg/lb) of body weight, and in general it is recommended that the maximum total dose does not exceed 300 mg. For continuous epidural or caudal anesthesia, the maximum recommended dosage should not be administered at intervals of less than 90 minutes. When continuous lumbar or caudal epidural anesthesia is used for non-obstetrical procedures, more drug may be administered if required to produce adequate anesthesia.

The maximum recommended dose per 90 minute period of lidocaine hydrochloride for paracervical block in obstetrical patients and non-obstetrical patients is 200 mg total. One half of the total dose is usually administered to each side. Inject slowly, five minutes between sides (see also discussion of paracervical block in PRECAUTIONS). 

For intravenous regional anesthesia, the dose administered should not exceed 4 mg/kg in adults.
Patients in the lorazepam arm will receive a bolus dose of 1-3 mg followed by an infusion started at 1-3 mg/hr. Lorazepam infusion will be titrated every 10 minutes to achieve set target RASS score. The maximum lorazepam infusion will be 10 mg /hr.
A supply tray for a surgical procedure is selected based on the surgical procedure and patient data retrieved from an electronic health records database. Multiple steps of the surgical procedure are retrieved from the electronic health records database. A message is sent to a first manipulator to move a supply from the supply tray to a staging area for performing a step. A first indication is received from a first sensor that the supply is needed at a present time. A position where the supply is needed in an operating area proximate to the staging area is determined using a second sensor. A second message is sent to a second manipulator to move the supply from the staging area to the position. A second indication is received from a third sensor that the step is complete. A third message is sent to a third manipulator to remove the supply.
OBJECTIVES: I. Determine the activity of interleukin-12 as defined by the percentage of patients who have not progressed after 6 months of therapy. II. Compare percentage of patients who have not progressed after six months with or without treatment regimen. III. Determine time to progression and overall survival in this patient population after this treatment.

OUTLINE: This is a randomized study. Patients are stratified according to disease free interval from primary diagnosis to first metastases (less than 3 years vs 3 years and longer), estrogen receptor status (positive vs negative), and disease status (complete response, partial response, detectable disease, or stable disease). Patients are randomized to one of two treatment arms. Arm I: Patients begin therapy no sooner than 3 weeks and no later than 6 weeks since last chemotherapy dose. Patients receive interleukin-12 subcutaneously twice a week. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed at least every 3 months for 1 year. If no progression after 1 year, may be followed as needed for new signs or symptoms and survival for 5 years. Arm II: Patients are observed for 6 months. If disease progresses during first 6 months, patients may receive interleukin-12 as in arm I. Patients without disease progression within first 6 months may also then receive interleukin-12 as in arm I. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed for toxicity only until interleukin-12 is discontinued.
The invention discloses a novel membrane fusion inhibitor for strongly inhibiting HIV and drug-resistant strains thereof, derivatives thereof, pharmaceutical compositions thereof and pharmaceutical uses thereof. The present invention provides lipopeptides, pharmaceutically acceptable salts thereof, or derivatives thereof. The structural formula of the lipopeptides is as follows: x is X  1  -polypeptide P1-X  2  Or X  3  -polypeptide P2-X  4  。X  1  /X  3  Is an amino-terminal protecting group of a polypeptide; x is X  2  /X  4  Is a carboxyl terminal protecting group of the polypeptide. The polypeptide P1 has the sequence EXEELEKKIELKKAEQKKNEEELKKKEK. The polypeptide P2 has the sequence EXEELEKKIELKKAEQKKKEQNEEELKKKX. The terminal amino acid residues of the polypeptides are modified with lipophilic compound groups. The lipopeptides of the invention have extremely strong inhibitory activity on HIV-1, HIV-2 and SIV, and particularly have remarkably improved inhibitory activity on T20 and LP-98 resistant HIV strains.
NSCLC patients who have failed first line TKI treatment (defined radiological documentation of disease progression during treatment for advanced or metastatic NSCLC with an approved EGFR-TKI e.g. gefitinib, afatinib or erlotinib) and are screened for the AURA3 study and determined to be lacking the T790M mutation as determined using the AURA3 designated central laboratory using the cobas® EGFR Mutation Test (Roche Molecular Systems).
The experimental group 1 (EG1) intervention comprises a psychomotor program. The program integrates 3 sessions / week of 75 minutes on alternated days. The psychomotor intervention includes exercises promoting simultaneous motor and cognitive stimulation (interval training).
FIELD: pharmaceutical and food industries. SUBSTANCE: invention relates to a disintegrating agent that is added to solid compositions. Invention proposes the solid composition of oral designation dissolving in mouth cavity that comprises disintegrating agent consisting of one or some substances taken among group including erythritol, trehalose, xylitol, maltose, potassium acetate, sodium acetate, sodium citrate, potassium hydrogen phosphate that are solid at the room temperature and exhibit solubility in water 36 wt. -% of above at 37 C. Saturated aqueous solution of this substance shows viscosity 50 mPa x s or less at 37 C where amount of disintegrating substance is 5-99 wt.-% relatively to the total mass of solid composition. EFFECT: improved properties of agent. 2 cl, 13 tbl, 3 dwg, 9 ex